Hormonal and Lipid Interactions in Patients with Concurrent Hypothyroidism and Type 2 Diabetes: A Focus on Prolactin and Testosterone Levels

Objectives: This study investigates the intricate biochemical interplay and endocrine dysregulation between hypothyroidism and type 2 diabetes, focusing on the roles of prolactin and testosterone as key hormonal biomarkers in metabolic regulation. It aims to elucidate how these hormonal imbalances contribute to glucose dysregulation, lipid abnormalities, and increased cardiovascular risk associated with overall metabolic dysfunction. Methods: A cross-sectional study was conducted on patients diagnosed with hypothyroidism, type 2 diabetes, or both. Biochemical parameters, including fasting blood sugar (FBS), postprandial blood sugar (PPBS), HbA1c, lipid profiles, prolactin, testosterone, and thyroid function tests (TSH, FT3, FT4), were analyzed. Correlation analysis was performed to determine the relationships between metabolic markers and hormonal levels. Results: Patients with concurrent hypothyroidism and diabetes exhibited significant elevations in FBS, PPBS, HbA1c, total cholesterol, LDL-C, and triglycerides, indicating compounded metabolic dysregulation and heightened cardiovascular risk. Elevated prolactin levels correlated with metabolic stress, suggesting an adaptive endocrine response to hyperglycemia and insulin resistance. Additionally, testosterone deficiency was observed in diabetic and hypothyroid patients, reinforcing its role in metabolic syndrome-related hypogonadism. Triglycerides emerged as a key metabolic marker, showing significant correlations with glucose and thyroid parameters. Conclusion: The interplay between prolactin, testosterone, and lipid metabolism highlights the need for a multidisciplinary approach in managing patients with coexisting hypothyroidism and diabetes. Routine endocrine evaluations focusing on these critical hormonal biomarkers, alongside lipid management strategies and targeted hormonal interventions, may enhance metabolic control and reduce long-term cardiovascular risk. Identifying prolactin, testosterone, and triglycerides as potential biomarkers could facilitate early diagnosis and personalized treatment strategies.